Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VTX3232 · 1 trial · 1 indication
Incidence of AEs and SAEs
| Arm | Type | Description |
|---|---|---|
| VTX3232 Dose A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VTX3232 | DRUG | Dose A |
Inclusion Criteria: * Participants must be ≥ 40 years up to 80 years of age, inclusive, at the time of signing the informed consent, with BMI \> 18.5 and \< 32.0 kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females. * Diagnosis of idiopathic Parkinson's Disease between 0 and 60 month...
VTX3232 is an investigational small molecule being developed for the treatment of idiopathic Parkinson disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
VTX3232 is being developed by Ventyx Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VTYX.
VTX3232 is in Phase 2 clinical development. It is an investigational drug and has not been approved for any use. A Phase 2a study has been completed.
VTX3232 has one completed clinical trial, NCT06556173, a Phase 2a study in Parkinson's disease. This trial enrolled 11 participants with idiopathic Parkinson disease in the United States.
VTX3232 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for idiopathic Parkinson disease, and its safety and efficacy have not been established.